Dr. Lal PathLabs to deploy the Galen™ platform, supporting
pathologists with multi-tissue, AI-driven insights in real
time
NEW DELHI, India, and
TEL AVIV, Israel, Nov. 24, 2021 /PRNewswire/ -- Dr. Lal PathLabs,
one of the largest chains of pathology labs in South East Asia, and Ibex Medical Analytics,
the market leader in artificial intelligence (AI)-powered cancer
diagnostics, today announced the first deployment in India of an AI platform that supports
pathologists during routine cancer diagnosis and helps improve the
quality and turnaround time of cancer tests.
Pathologists play a crucial role in the detection and diagnosis
of disease, with their assessments vital in reaching correct
treatment decisions by oncologists. However, a rise in cancer
prevalence and advances in personalized medicine have resulted in
growing diagnostic complexity, which significantly increases
pathologists' workloads. Today, as pathology labs are transitioning
towards digital solutions, pathologists can implement AI-enhanced
workflows to improve the quality and efficiency of cancer
diagnosis, resulting in better patient care.
Ibex's AI technology and Philips' IntelliSite pathology solution
demonstrated impressive performance across multiple clinical
studies and in live clinical deployments in Europe and the
United States. This partnership marks a continued journey to
find the most innovative products that help patients and
doctors.
"Ibex is committed to providing every patient with a precise,
timely and personalized cancer diagnosis, made available by our AI
technology that supports real-world needs from physicians," said
Stuart Shand, Chief Commercial
Officer at Ibex Medical Analytics. "We are delighted to work
together with Philips and Dr. Lal PathLabs to empower their
pathologists to provide highly accurate and prompt diagnoses with a
potential of directly impacting prognosis for patients. Artificial
intelligence is becoming the new standard in cancer care, a vision
embraced by our companies."
Ibex transforms cancer diagnosis by harnessing artificial
intelligence and machine learning technologies at an unprecedented
scale. Ibex's Galen platform helps pathologists improve the quality
of cancer diagnosis, implement real-time quality
control1, reduce diagnosis time and boost
productivity2. The platform was recently granted
Breakthrough Device Designation by the U.S. Food and Drug
Administration (FDA) and is CE marked in Europe for breast and prostate cancer
detection in multiple workflows. Galen has already demonstrated
outstanding outcomes in clinical studies3,4, and has
been deployed in labs worldwide where it is used as part of
everyday clinical practice.
Dr. Lal PathLabs is a large histopathology processing centre
with up-to 1400 surgical pathology samples a day translating to
more than a million slides annually. Dr. Lal PathLabs was among the
pioneers in adopting digital pathology in India by deploying Philips Intellisite
Pathology Solutions (PIPS) which delivers WSI (Whole Slide Images)
of high-resolution digitized pathology slides. We are amongst the
first laboratories in the country to implement artificial
intelligence in diagnostic pathology. By adding Ibex's Galen
platform, pathologists at Dr. Lal Pathlabs will benefit from
automated, clinical-grade AI insights on multiple types of tissue,
supporting quality diagnosis delivered on shorter turnaround
times.
"This cutting-edge AI technology will help our pathologists
quickly prioritise urgent cases and improve quality by adding an
'AI review'," said Dr. Reena Nakra,
Principal Director Lab Management and Technical Excellence, Dr. Lal
PathLabs Ltd. "These AI-generated insights include cancer heatmaps,
tumour grading and measurement and streamlined reporting tools
enabling a digital assistance to the oncopathologist."
About Dr. Lal PathLabs
Dr. Lal PathLabs Ltd is one the largest chain of pathology labs
in SE Asia. We
at Dr. Lal PathLabs have committed ourselves to a vision. A
vision to dedicatedly improve the health of patients through
unsurpassed diagnostic insight and keeping our approach 'Patient
Centric'. The diagnostic chain has a network of around
230+ clinical laboratories pan India with an extensive hub and spoke model of
around 1600 collection centers and associate partners in
India and outside India in sixteen countries.
As a leading diagnostic service provider, Dr. Lal PathLabs holds
coveted accreditations from the College of American Pathologists
(CAP) and the National Board for Accreditation of Laboratories NABL
for an extensive test menu of 5000+ tests & panels and
the ISO 27001 accreditation for their IT systems to stand testimony
to the practice of accuracy, efficiency and customer
service. We have consistently delivered on
international standards in testing to over 20 million customers
annually. Dr. Lal PathLabs is listed on National
Stock Exchange (NSE) India, making
the organisation the first one to go public in the Indian
Diagnostics Industry. At Dr. Lal PathLabs, 'Quality, Service
and Innovation is a way of life'. For more information visit us at
www.lalpathlabs.com.
About Ibex Medical Analytics
Ibex pioneers AI-powered cancer diagnostics in pathology. We
empower physicians to provide every patient with an accurate,
timely and personalized cancer diagnosis by developing
clinical-grade AI algorithms and digital workflows that help detect
and grade cancer in biopsies. Our Galen™ platform is the first-ever
AI-powered integrated diagnostics solution in pathology and used in
routine clinical practice worldwide, supporting pathologists and
providers in improving the quality and accuracy of diagnosis,
implementing comprehensive quality control, reducing turnaround
times and boosting productivity with more efficient workflows.
Ibex's Artificial Intelligence technology is built on Deep Learning
algorithms trained by a team of pathologists, data scientists and
software engineers. For more information, go
to www.ibex-ai.com.
About Philips
Royal Philips (NYSE: PHG, AEX:
PHIA) is a leading health technology company focused on improving
people's health and well-being, and enabling better outcomes across
the health continuum – from healthy living and prevention, to
diagnosis, treatment and home care. Philips leverages advanced
technology and deep clinical and consumer insights to deliver
integrated solutions. Headquartered in the Netherlands, the company is a leader in
diagnostic imaging, image-guided therapy, patient monitoring and
health informatics, as well as in consumer health and home care.
Philips generated 2020 sales of EUR 17.3
billion and employs approximately 78,000 employees with
sales and services in more than 100 countries. News about Philips
can be found at www.philips.com/newscenter.
Media Contact -
International
Yael Hart
GK for Ibex
yael@gkpr.com
Media Contact - India
Rakshit
Tewari
Associate Director
AdfactorsPR, Delhi
rakshit.tewari@adfactorspr.com
[1] Sandbank J et al, Deployment of a Multi-Tissue
AI-based Quality Control System in Routine Clinical Workflow.
European Conference of Pathology 2020:
https://ibex-ai.com/wp-content/uploads/2021/03/Maccabi-IBEX-ECP2020-poster.pdf
[2] Raoux D, et al, Novel AI Based Solution for
Supporting Primary Diagnosis of Prostate Cancer Increases the
Accuracy and Efficiency of Reporting in Clinical Routine. USCAP
2021: https://www.youtube.com/watch?v=9XuWK8PmUlw
[3] The LANCET Digital Health, Aug 2020, Pantanowitz et al, An artificial
intelligence algorithm for prostate cancer diagnosis in whole slide
images of core needle biopsies: a blinded clinical validation and
deployment study
https://www.thelancet.com/journals/landig/article/PIIS2589-7500(20)30159-X/fulltext
[4] Laifenfeld D et al, AI-Based Solution for Cancer
Diagnosis in Prostate Core Needle Biopsies: A Prospective Blinded
Multi-Site Clinical Study. USCAP 2021:
https://www.youtube.com/watch?v=9nDiJY90v9c
Photo -
https://mma.prnewswire.com/media/1695347/Ibex_with_Dr_Lal_PathLabs_and_Royal_Philips.jpg